Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Reference: Multiple RA collaboration - I believe this new initiative was mentioned by Senti a few months ago, but here’s the latest:
“FDA takes first action under new international collaboration with Australia and Canada designed to provide a framework for concurrent review of cancer therapies, approving treatment for patients with endometrial carcinoma”
https://www.fda.gov/news-events/press-announcements/fda-takes-first-action-under-new-international-collaboration-australia-and-canada-designed-provide
Project Orbis:
https://www.fda.gov/about-fda/oncology-center-excellence/project-orbis?utm_campaign=091719_PR_FDA+takes+first+action+under+new+international+collaboration&utm_medium=email&utm_source=Eloqua
Thanks for your reply abeta....
If there is interest in INMB, Dr. Tesi is presenting INMB’s new product to at a conference this afternoon and webcast is available.
“LA JOLLA, Calif., Sept. 05, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is pleased to announce that R.J. Tesi, M.D., the Company’s Co-founder and CEO, is scheduled to present at the H.C. Wainwright 21st Annual Healthcare Conference in New York City to introduce the NeuLiv™ program for treatment of NASH."
INMB's site page re conference with webcast link:
https://www.inmunebio.com/index.php/en/news-2/2019/291-muneiotoresentattheainwright21stnnuale20190905
In checking NWBIO site - something interesting just before market open:
This site is currently undergoing scheduled maintenance.
Please try back soon!
How gracious
Thnx
Always appreciate a correcting lesson
Thnx
Jim Cramer interviewed Wm Doyle, Executive Chairman, Novocure, on Mad Money a few hours ago:
https://www.cnbc.com/video/2019/08/13/novocure-chairman-education-helped-us-reach-positive-operating-income.html
Has new filing been posted? Apologies if this is duplicate.
10Q Filing
https://www.sec.gov/cgi-bin/browse-edgar?company=Northwest+Biotherapeutics&owner=exclude&action=getcompany
INmune Bio (NWBO’s cousin) PR today:
https://www.inmunebio.com/index.php/en/news-2/2019/280-muneiooounderandresentsat17thnnualongr20190725
Cognate BioServices
Just posted a new position - Director of Marketing
https://www.linkedin.com/jobs/search?keywords=Cognate%20BioServices&location=Memphis%2C%20Tennessee%2C%20United%20States&trk=homepage-basic_jobs-search-bar_search-submit&pageNum=0&position=8&redirect=false¤tJobId=1369431812
Eval…sorry my link is misbehaving for you.
The link you offered has a date of Feb 2019 and my link was from today with a date on the presentation of 6.17.19. I don’t know if the new presentation carries changes or not but perhaps some of our posters are following INMB and may note them if that is the case. In any event, INMB’s website lists their filings and the latest 8K is there.
You are deserving of high respect, admiration, and thoughts of comfort from all of us.
Republican Senators Prod FDA to Expand Parallel Track
June 5, 2019
Four Republican senators are urging Acting FDA Commissioner Ned Sharpless to expand the agency’s Parallel Track program to give patients with incurable diseases a chance at recovery.
Regulators launched Parallel Track in 1992 to give HIV/AIDS patients access to treatments that hadn’t been approved yet. Now, Sens. Ted Cruz (R-Texas), Rand Paul (R-Ky.), Mike Braun (R-Ind.) and Mike Lee (R-Utah), say they want the program expanded to dementia, cancer and ALS.
The letter carries none-too-subtle threats about Sharpless’ future—and the agency’s funding. “As we examine the budget of the FDA and its potential new leadership,” it says, “we are looking for evidence that the agency seeks to act as a bridge—not a barrier—to innovation.”
The letter implies that former Commissioner Scott Gottlieb resisted efforts to expand Parallel Track. It opens, “With the change in leadership” at the agency, “there is a unique opportunity for the FDA to better prioritize bringing life-saving drugs to patients faster and at a lower cost.”
https://www.fdanews.com/articles/191517-republican-senators-prod-fda-to-expand-parallel-track
Thoughts and prayers on their way.
No one would ever call you a “kill joy;” you’re a KOL
on this MB.
My deepest sympathy for your loss, Captain
Thanks for your extra effort Poor Man and sharing with the MB
“All I heard is this will be his first external meeting with the stakeholders outside of FDA. This is where Dr. Liau is there and Dr. Liau is the PI of our DcVaxL. Any significance to his visit to UCLA?? Must be I guess. Otherwise there are hundreds of places to visit on the earth, why going there? He is a cancer doc by degree and LP worked for him in the past. FDA is looking for a parallel therapy to CAR-T to treat solid cancers and L and D fit perfectly there, in fact, like flipper teaches us much better than that. Must be something I bet.”
Speaking of UCLA….in case anyone missed this announcement:
UCLA’s Antoni Ribas named American Association for Cancer Research President-Elect
https://cancer.ucla.edu/Home/Components/News/News/1278/1631
Marzan….thank you for this contribution to the board. Great way to start the day.
Thanks for sharing
Thanks for supporting
Thanks for your DD
Best
AI4door….
You are correct in that NWBO has had a large booth at ASCO for many years. It would seem that they, like many of us, expected their story to take flight and not have a boot on their throat these many years.
Additionally, it is the norm for convention/show management companies to offer “first right of refusal” to exhibitors that have consistently paid the high costs for a larger presence. At this critical time, NWBO is certainly not going to relinquish their high-profile booth.
Apologies if this was published earlier today:
Gottlieb:…15 March 2019
https://www.fiercebiotech.com/biotech/gottlieb-criticizes-sponsors-continued-reluctance-to-rethink-clinical-trials
“NWBO will make it blatantly clear that they are not to blame for delays to patient access to their products. Mr. Cofer Black will make sure of that. I am absolutely certain that he has a really good story to tell now and that story will be used as motivation for one and all who have stood in the way of this technology reaching patients just like water boarding and other techniques were used in Iraq and elsewhere.”
Excellent! Bravo! Booyah!
I agree as well H2R...and, thanks for the added info